Canada should give biopharmaceutical firms patent term extensions to recover time lost due to mandatory regulatory and marketing approvals.
Canadian policy-makers should enact legislation to define rare diseases and encourage Canadian firms to intensify their research and development of new therapies, writes Kristina Lybecker. Victor Casale photograph courtesy of Flickr
VANCOUVER, B.C. / Troy Media/ – As the old adage states, “You’ll be known by the company you keep.” As such, the implications for Canada’s biopharmaceutical sector are rather dismal.
People. Policy. Politics. This is an exclusive subscriber-only story.
Small Business Minister Mary Ng says the extent of her interactions with the organization was limited to that initial pitch, and did not extend to the since-cancelled contract for the student-grant program.
Cherie Wong of the Alliance Canada Hong Kong says Canada’s intelligence and police agencies appear to be ill-equipped to respond to the 'malicious and sophisticated' ways in which Beijing allegedly suppresses criticism.